NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
12 Jun 2017

TiGenix announces final equity payment for cardiac platform acquisition

TiGenix NV today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015. 
01 Jun 2017

EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain

The European Investment Bank is supporting the improvement of infectious diseases diagnostics through a EUR 20 million loan agreement signed today with STAT-Dx.
23 May 2017

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds.

Anaconda Biomed, announces it has closed a Series A financing of 15 million Euro.
22 May 2017

AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury

AM‐Pharma B.V., announced completion of recruitment in the adaptive Phase II trial to treat sepsis patients with Acute Kidney Injury (AKI).
04 May 2017

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

Vivet Therapeutics (‘Vivet’), announced it has raised €37.5 million in a Series A financing round.
01 May 2017

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals, Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.
21 Apr 2017

STAT-Dx Unveils New In-Vitro Diagnostic System DiagCORE®

TAT-Dx, is unveiling DiagCORE®, its fully-integrated platform for multiplex real-time PCR diagnosis, at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
06 Apr 2017

TiGenix reports 2016 full year results

TiGenix NV today reported its business and financial highlights for 2016 and post year-end events.
05 Apr 2017

Aelix Therapeutics appoints Dr. Ian McGowan as Chief Medical Officer

Aelix Therapeutics, today announces the appointment of Dr. Ian McGowan as Chief Medical Officer, effective March 1, 2017.
Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma<
30 Mar 2017

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma

Aura Biosciences, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light-activated AU-011.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.